Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Santhera Pharmaceuticals Holding AG
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
April 25, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
March 27, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
March 14, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
February 14, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
January 15, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom
January 12, 2024
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
December 18, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
December 07, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
October 27, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy
October 13, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
September 07, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group
July 31, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone
July 19, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Publishes Timeline of the Reverse Share Split
June 29, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Shareholders Approve all Board Proposals at Today’s Annual General Meeting
June 27, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties
June 20, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Publishes Agenda for its Annual General Meeting
June 06, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Publishes Annual Report 2022
May 31, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
April 27, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Vamorolone NDA mid-cycle review meeting by FDA completed
April 25, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Submits Marketing Authorization Application to the UK MHRA for Vamorolone in Duchenne Muscular Dystrophy
March 02, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement
February 28, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Concludes Agreement with French Authorities on Raxone® Reimbursement and Plans to Submit a Request for an Early Access Program for Vamorolone
February 08, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera enters into CHF 5 million share exchange agreement
January 10, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera and ReveraGen Announce FDA Acceptance of New Drug Application for Vamorolone in Duchenne Muscular Dystrophy
January 09, 2023
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting
November 29, 2022
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings
November 04, 2022
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
European Medicines Agency Validates Santhera’s Marketing Authorization Application for Vamorolone in Duchenne Muscular Dystrophy
October 31, 2022
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
October 31, 2022
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Santhera and ReveraGen Complete NDA Submission to FDA for Vamorolone in Duchenne Muscular Dystrophy
October 27, 2022
From
Santhera Pharmaceuticals Holding AG
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.